Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Please review our Privacy Policy to learn more. 

Skip to Content

For everyone's safety, masks are required for everyone in our facilities. This includes visitors and patients. View visitor policy.

the beat

The Beat:
A Bryan Heart Blog

The Beat is a monthly blog from Bryan Heart cardiologists to keep you informed on trending topics, advancements and news in heart care.

Subscribe to receive The Beat to your inbox monthly.

Bryan Heart

To refer a patient to a Bryan Heart cardiologist or surgeon, call 402-483-3333.

Learn about Bryan Heart

Mitra Clip: Treatment of Secondary Mitral Regurgitation

Written by John Steuter, MD

The MitraClip device is already approved in the U.S. for use in primary mirtal regurgitation (MR), a condition in which the mitral valve leaflets do not function properly due to a degenerative defect.

Whether the device is useful for secondary MR, in which the valve structure is normal, but the ventricle is enlarged, has still been in question. The prognosis for heart failure patients who develop severe secondary mitral regurgitation is poor with limited treatment options.

COAPT Trial Investigates MitraClip Effectiveness for Secondary MR

COAPT was a randomized, parallel-controlled, open-label multicenter trial evaluating transcatheter mitral valve repair with the MitraClip device in symptomatic heart failure patients with moderate-to-severe or severe secondary MR.

  • 614 subjects were randomized at 78 centers in the United States and Canada
  • 302 patients were assigned to the device and guideline-directed medical therapy (GDMT) in the device group
  • 312 patients were assigned to GDMT alone in the control group


Photo courtesy of

mitraclip use

Photo courtesy of Northwestern Medicine

The Results: Impressive

The primary effectiveness endpoint was the annualized rate of all heart failure hospitalizations through 24 months and the primary safety endpoint was freedom from device-related complications at 12 months.

The annualized rates of heart failure hospitalization were 35.8% per patient-year in the device group versus 67.9% per patient-year in the control group.

All-cause mortality at 24 months with the device was 29.1% compared to 46.1% in the control group.

This procedure adds an important option for high-risk heart failure patients with secondary MR who remain symptomatic despite optimal medical therapy.

Advanced MR Therapy at Bryan Heart

At Bryan Heart we are proud to provide this therapy and many other advanced cardiac treatments for our patients. For questions or to refer a patient, call 402-483-3333.

steuter john

About John Steuter, MD

John Steuter, MD, is a cardiologist at Bryan Heart. Steuter is a graduate of The University of Nebraska Medical Center College of Medicine and joined Bryan Heart in 2015 after completing his residency and fellowship at The University of Nebraska Medical Center. He is certified with the American Board of Internal Medicine.

View Dr. Steuter’s physician profile


Copyright 2022 Bryan Health. All rights reserved.